¼¼°èÀÇ ¸»ÃÊÇ÷°ü ±â±â ¾÷°è(2024-2029³â)
Peripheral Vascular Devices Industry, Global, 2024-2029
»óǰÄÚµå : 1735877
¸®¼­Ä¡»ç : Frost & Sullivan
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 54 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 6,791,000
Web Access (Regional License) help
Frost & SullivanÀÇ À¥»çÀÌÆ® ·Î±×ÀÎ ÆÐ½º¿öµå°¡ ¹ßÇàµÇ¸ç, PDF¸¦ ´Ù¿î·Îµå ¹Þ´Â ÇüÅ·ΠÁ¦°øµÉ ¿¹Á¤ÀÔ´Ï´Ù. PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù


Çѱ۸ñÂ÷

¾à¹° ¿ëÃâ ½ºÅÙÆ® ¹× ¾à¹° ÄÚÆÃ Ç³¼± Çõ½ÅÀ¸·Î Çõ½ÅÀû ¼ºÀå ÃËÁø

Frost & SullivanÀº ¿¹Ãø ±â°£ µ¿¾È ¾à¹° ¿ëÃâ ½ºÅÙÆ® ¹× ¾à¹° ÄÚÆÃ Ç³¼±À¸·ÎÀÇ ÀüȯÀÌ ¸»ÃÊÇ÷°ü ÀåÄ¡ »ê¾÷À» À̲ô´Â ÁÖ¿ä Æ®·»µå°¡ µÉ °ÍÀ¸·Î º¸°í ÀÖ½À´Ï´Ù. »ýÈí¼ö¼º ½ºÄ³Æúµå¿¡ ´ëÇÑ ÅõÀÚ°¡ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¾à¹° ¿ëÃ⼺ »ýÈí¼ö¼º ½ºÄ³Æúµå´Â ¾÷°è °ü°èÀÚµé »çÀÌ¿¡¼­ °ü½ÉÀÌ ³ôÀº ºÐ¾ßÀÔ´Ï´Ù. ¶ÇÇÑ, ¸»Ãʵ¿¸ÆÁúȯ, ƯÈ÷ ¹«¸­ ¾Æ·¡ ¸»Ãʵ¿¸ÆÁúȯ°ú »çÁö Àý´ÜÀ¸·Î À̾îÁú ¼ö ÀÖ´Â ¸¸¼º ÇãÇ÷¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ ¼Ö·ç¼Ç °³¹ß¿¡ ´ëÇÑ °ü½ÉÀº ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ÀÌ º¸°í¼­´Â ±Ý¼Ó ½ºÅÙÆ®, »ýüÈí¼ö¼º ½ºÅÙÆ®, ¾à¹° ¿ëÃâ ½ºÅÙÆ®, ¾à¹° ÄÚÆÃ Ç³¼±, °æÇÇÀû °æ°ü Ç÷°ü¼ºÇü¼ú(PTA) dz¼±, Ä«Å×ÅÍ µî ¸»ÃÊÇ÷°ü ±â±â¸¦ ºÐ¼®ÇÕ´Ï´Ù. ºÐ¼® Áö¿ªÀº ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«·Î ³ª´µ¾îÁ® ÀÖ½À´Ï´Ù. »ê¾÷ ±Ô¸ð, ¼ºÀå·ü, ¼ºÀå ±âȸ, Àü·«Àû °úÁ¦, ȯÀÚ °æ·Î, ±â¾÷ ½ÃÀå Á¡À¯À², ½Ã¼ú µ¿Çâ, ½Å±â¼ú, ÃÖÁ¾»ç¿ëÀÚ¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

Á¶»ç±â°£Àº 2021³âºÎÅÍ 2029³â±îÁö, ±âÁØ ¿¬µµ´Â 2024³â, ¿¹Ãø ±â°£Àº 2024³âºÎÅÍ 2029³â±îÁöÀÔ´Ï´Ù.

¸ñÂ÷

Á¶»ç ¹üÀ§

¼ºÀå ȯ°æ : ¸»ÃÊÇ÷°ü ±â±â ¾÷°èÀÇ Àüȯ

¸»ÃÊÇ÷°ü ±â±â ¾÷°èÀÇ »ýŰè

¸»ÃÊÇ÷°ü ±â±â ¾÷°èÀÇ ¼ºÀå Á¦³Ê·¹ÀÌÅÍ

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : ºÏ¹Ì

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : À¯·´

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : ¾Æ½Ã¾ÆÅÂÆò¾ç

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : ¶óƾ¾Æ¸Þ¸®Ä«

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

¸»ÃÊÇ÷°ü ±â±â ¾÷°èÀÇ ¼ºÀå ±âȸ À¯´Ï¹ö½º

ºÎ·Ï°ú ´ÙÀ½ ´Ü°è

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Innovations in Drug-eluting Stents and Drug-coated Balloons are Driving Transformational Growth

Frost & Sullivan observes that the shift to drug-eluting stents and drug-coated balloons will be the key trends driving the peripheral vascular devices industry during the forecast period. Investments in bioresorbable scaffolds will further drive the market growth. Drug-eluting bioresorbable scaffolds are an area of interest among industry stakeholders. Moreover, interest in developing innovative solutions for peripheral artery disease, especially below-the-knee peripheral artery disease and complex chronic limb-threatening ischemia, positively impacts the market growth.

This study analyzes peripheral vascular devices, such as metal stents, bioresorbable stents, drug-eluting stents, drug-coated balloons, percutaneous transluminal angioplasty (PTA) balloons, and catheters. Regional coverage includes North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The study provides insights into industry size, growth rates, growth opportunities, strategic imperatives, patient pathways, company market share, procedure trends, new technologies, and end users.

The study period is from 2021 to 2029, the base year is 2024, and the forecast period is from 2024 to 2029.

Table of Contents

Research Scope

Growth Environment: Transformation in the Peripheral Vascular Devices Industry

Ecosystem in the Peripheral Vascular Devices Industry

Growth Generator in the Peripheral Vascular Devices Industry

Growth Generator: North America

Growth Generator: Europe

Growth Generator: Asia-Pacific

Growth Generator: Latin America

Growth Generator: Middle East and Africa

Growth Opportunity Universe in the Peripheral Vascular Devices Industry

Appendix & Next Steps

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â